The innovation hub located in Songdo, Incheon, will feature both a manufacturing facility and a customer experience lab. The manufacturing facility is expected to begin operations in 2026, focusing on producing high-quality filtration products.
Global life sciences leader Cytiva has opened its first innovation hub in Korea, located in the Songdo bio-cluster in Incheon. The purpose of this new facility is to serve as a cornerstone for innovation and excellence, advance biopharmaceutical manufacturing, and meet the emerging needs of Cytiva’s customers in Korea and the broader APAC region.
At the inauguration ceremony held on September 30, key government officials from the Incheon Free Economic Zone Authority (IFEZ) and the Korea Trade-Investment Promotion Agency (KOTRA) were in attendance. Leaders from Cytiva and other industry-leading companies such as Samsung Biologics, Samsung Bioepis, Celltrion, SK Bioscience, and Lotte Biologics were also present.
Won-Seok Yoon, the Commissioner of the Incheon Free Economic Zone (IFEZ), highlighted that Cytiva’s innovation hub reinforces Songdo’s standing as a global leader in the biotech space. He expressed enthusiasm about continuing the partnership with Cytiva, saying, “We look forward to discovering new opportunities to drive the growth of our local bio industry, especially by focusing on programs that train bio professionals.”
Jongkue Yoon, Vice President of Samsung Biologics, expressed his enthusiasm as well, stating, “As demand for biopharmaceuticals continues to rise, Cytiva’s new manufacturing facility in Korea is a major win for pharmaceutical and biotech companies. I firmly believe that by working closely with Cytiva through this innovation hub, we will greatly enhance the competitiveness of Korea’s life sciences sector.”
A New Era of Innovation and Collaboration
Spanning nearly 6,100 square meters, the innovation hub houses a manufacturing facility for delivering essential products used in therapeutic development, along with a customer experience lab for product demonstrations.
Aligned with Cytiva’s dedication to sustainability, the facility will operate in accordance with net-zero environmental impact guidelines. It will incorporate various sustainable construction practices aimed at improving energy and water efficiency, achieving zero landfill waste, and reducing CO2 emissions.
Junho Choi, Cytiva Korea’s Commercial General Manager, said, “We hope this innovation hub will not only help foster growth for our Korean customers but also play a key role in the APAC biopharmaceutical market. This facility will enhance customer engagement and collaboration, promoting innovation and excellence in the region.”
Strengthening Korea’s Biopharma Industry and Beyond
This new facility is a key component of Cytiva’s broader strategy to address the growing demands of the biopharmaceutical industry in Korea and the wider APAC region.
By adopting sustainable manufacturing practices, Cytiva aims to provide environmentally-friendly solutions to its Korean customers that support industry growth, benefit the market, and help meet environmental goals.